Abraxis Biosciences Inc. (ABII) To Test Resistance Level Around $55.40
By Mark Moneymaster
March 17, 2010 1:12 PM
March 17, 2010 1:12 PM
Symbols: ABII
Abraxis Biosciences Inc. (NASDAQ: ABII) rallied nearly 32% to $51.53, following the positive Phase III clinical results for Abraxane, its drug candidate for treating lung cancer. Abraxis Biosciences Inc. (ABII) said it tested Abraxane in combination with leading chemotherapy drugs Taxol and carboplatin in patients with lung cancer.
The wide gap-up opening in Abraxis Biosciences Inc. (ABII) on Wednesday took the stock closer to its 52 week high of $57.60. Abraxis Biosciences Inc. (ABII) is likely to test an immediate resistance of $55.40 before it is able to breach above its trailing 52 week high.
(c) 2011 Benzinga.com. All rights reserved. This material may not be published in its entirety or redistributed without the approval of Benzinga.
We're Loving
